Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BL M07D1

X
Drug Profile

BL M07D1

Alternative Names: BL-M07D1

Latest Information Update: 20 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Baili Pharmaceutical; SystImmune
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA damage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Gastric cancer

Highest Development Phases

  • Phase I/II Gynaecological cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Breast cancer; Gastric cancer

Most Recent Events

  • 24 Apr 2024 Phase-I/II clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06114511)
  • 19 Mar 2024 Sichuan Baili pharmaceutical plans a phase III trial in HER2-positive breast cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in China (IV) in April 2024 (NCT06316531)
  • 29 Feb 2024 Phase-I/II clinical trials in Gynaecological cancer (Recurrent, Metastatic disease, In adults, In the elderly) in China (IV) (NCT06131450)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top